CING (Cingulate Corp) Net earnings per share growth this year

Official company branding of Cingulate Inc. (CING)

Cingulate Inc. is based on precision drug-release technology for ADHD to ensure a stable effect. The 12-month earnings per share growth rates confirm market dynamics, where the 52.00 level captures fresh values. Partnerships with clinics are advancing therapy methods, however, the completion of programs is accompanied by rising research costs in the absence of current sales.

CING (cingulate.com) Earnings per share growth in current year history from 07/04/2022 to 11/10/2026

Financial and market metric breakdowns for cingulate.com (CING)

- stock value and consensus price forecast:
Market Price Cingulate|CING - Analyst Consensus Forecast
- business market valuation indicators:
Market Valuation Cingulate Inc.|CING - Enterprise Value
- company book value details:
Accounting Value of a Share Cingulate|CING - Company Book Value|Market-to-Book Ratio cingulate.com|CING - Company Total Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Cingulate Inc.|CING - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Cingulate|CING - Company Debts|Debt to Book Value Ratio Cingulate Inc.|CING - Company Long-Term Debts|Short-Term Indebtedness Cingulate|Quick Ratio cingulate.com
- net income and valuation multiples indicators:
CING - Company Net Income|Expected Profit Cingulate Inc.|CING - P/E Multiple|Forward P/E Multiple Cingulate|CING - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Cingulate Inc.|CING - Operating profit EBITDA|Net earnings per one share for the last twelve months Cingulate|CING - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months cingulate.com|CING - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Cingulate Inc.
Basic company analysis:Cingulate Corp
Core merchandise of Cingulate Corp

Cingulate Inc. minimizes clinical trial risks by diversifying dosages of drugs for the treatment of psychiatric disorders. An analysis of annual earnings per share volatility allows these strategies to be mapped against financial results. This metric captures the percentage deviation of current earnings per share from the previous year's value. This indicator reveals the real balance of returns by filtering out market noise. A stable trend confirms the resilience of the issuer's capital.

Direct competitors

Earnings per share growth rate in current year Alkermes PLC (ALKS)|AVDL (Avadel Pharma) - Earnings growth in current year|Net earnings per share growth this year atai (ATAI)|Earnings growth in current year GHRS|MNMD (mindmed.co) - Earnings per share increase in current year|Earnings per share growth in current year COMPASS Pathways CMPS|LB Pharmaceuticals, Inc. (LBRX) - Earnings per share growth rate in current year|Bright Minds Biosciences Inc - Earnings growth in current year|Vanda (VNDA) - Net earnings per share growth this year|CYBN: Earnings growth in current year|ANRO - Expected net earnings per share growth this year|Earnings per share growth in current year NRx Pharmaceuticals, Inc.|Earnings per share growth this year SILO (Silo Pharma Inc.)|Earnings growth in current year CPHI|clearmindmedicine.com (CMND) - Net earnings per share change in current year|Psyence Biomedical Ltd. - Net earnings per share growth this year|Earnings growth in current year scisparc.com SPRC|SEEL - Earnings per share growth in current year|VRPX: Earnings per share growth in current year|KRTX: Earnings growth in current year